Background: Known risk factors for secondary lymphedema only partially explain who develops lymphedema following cancer, suggesting that inherited genetic susceptibility may influence risk. Moreover, identification of molecular signatures could facilitate lymphedema risk prediction prior to surgery or lead to effective drug therapies for prevention or treatment. Recent advances in the molecular biology underlying development of the lymphatic system and related congenital disorders implicate a number of potential candidate genes to explore in relation to secondary lymphedema. Methods and Results: We undertook a nested case-control study, with participants who had developed lymphedema after surgical intervention within the first 18 months of their breast cancer diagnosis serving as cases (n = 22) and those without lymphedema serving as controls (n = 98), identified from a prospective, populationbased, cohort study in Queensland, Australia. TagSNPs that covered all known genetic variation in the genes SOX18, VEGFC, VEGFD, VEGFR2, VEGFR3, RORC, FOXC2, LYVE1, ADM, and PROX1 were selected for genotyping. Multiple SNPs within three receptor genes, VEGFR2, VEGFR3, and RORC, were associated with lymphedema defined by statistical significance ( p < 0.05) or extreme risk estimates (OR < 0.5 or > 2.0). Conclusions: These provocative, albeit preliminary, findings regarding possible genetic predisposition to secondary lymphedema following breast cancer treatment warrant further attention for potential replication using larger datasets.
Introduction
L ymphedema is one of the most problematic complications following breast cancer treatment, experienced by approximately 30% of breast cancer survivors. [1] [2] [3] It represents failure of the lymphatic system to adequately drain fluid and proteins from the interstitial tissue and to circulate lymphocytes. Removal or damage to the lymph nodes or lymphatic vasculature during cancer treatment may impede proper physiological function of this network. Although lymphedema can occur in any part of the body, it generally refers to an accumulation of fluid and subsequent distortion of a limb. 4 Little is known about its prevention, and it is regarded as an incurable, progressive, disfiguring, and disabling disorder that is difficult to manage, compromising function 5 and quality of life. 6 Lymphedema may present immediately or years after breast cancer treatment, 7 although the majority of cases seem to appear within the first 12-18 months post-surgery. 3, [8] [9] The published literature on risk factors is characterized by inconsistent relationships, but evidence is mounting for a few, including extent of surgery, extent of lymph node resection, radiation therapy, obesity, and surgical wound infection. 10 Nevertheless, it is clear that these characteristics only partially explain who develops lymphedema, and lymphedema can and does occur in women lacking these risk factors. It is therefore possible that inherited genetic susceptibility may play a role in the pathogenesis of secondary lymphedema.
There has been substantial progress in identifying genes that contribute to development of the lymphatic vascular system during embryogenesis and its subsequent regulation. [11] [12] [13] [14] Some genes are now known to underlie primary lymphedema, [15] [16] [17] [18] a congenital or later-onset condition that occurs in the absence of any known injury or medical intervention, and findings from genetic studies of inherited lymphedema assist with the molecular dissection of lymphatic diseases. 19 We hypothesized that genes involved in familial lymphedema (VEGFR3 (flt4), FOXC2, 20 and SOX18 15 ) and/or lymphangiogenesis in the embryo, such as VEGFC, VEGFD (also known as FIGF), VEGFR2 (KDR), RORC, LYVE1, ADM (Adrenomedullin), and PROX1, [20] [21] [22] may also predispose to secondary lymphedema. We therefore undertook a comprehensive investigation of genetic variation in these 10 plausible candidate genes in a cohort of breast cancer survivors, to assess the role of inherited genetic susceptibility in the development of secondary lymphedema after breast cancer.
Materials and Methods
The study was a nested case-control design involving participants who had developed lymphedema within the first 18 months of their breast cancer diagnosis serving as cases and those without lymphedema serving as controls, identified from a prospective, population-based, cohort study called the 'Pulling Through Study' (PTS) conducted in Queensland, Australia.
Study design and sample recruitment of the original 'Pulling Through Study'
Recruitment and study design for the PTS have been described in detail elsewhere. 9 In brief, 417 women with primary, unilateral, invasive breast cancer, diagnosed in 2002, were randomly selected from the Queensland Cancer Registry and invited to participate in the PTS. Of these, informed consent was obtained for 68% (n = 287). Starting at 6 months post-diagnosis, women were prospectively followed for 12 months, with data collection procedures involving completion of a clinical assessment and/or self-administered questionnaire every 3 months. Lymphedema status was evaluated using the sum of arm circumferences (SOAC) method. 23 A woman who scored a difference of > 5 cm between the treated and untreated sides, during any of the five data collection sessions between 6 and 18 months post-diagnosis, was considered a lymphedema case. The remaining women were considered controls. Some of the women (26%) participated on a questionnaire-only basis; hence they lack objective assessments of lymphedema and therefore were not available for inclusion in these analyses.
Design and sample recruitment of the nested case-control study
The follow-up, nested case-control study reported here commenced approximately 6 years following the date of breast cancer diagnosis for those in the PTS. Of the 287 original participants, 11 withdrew from the study and 16 had died (identified through the Queensland Cancer Registry mortality database), leaving 260 women to be re-contacted. Address details were checked with the electronic White Pages, and a change of address search was carried out through Australia Post. When an address could not be confirmed from these sources, the last postal address recorded in our files was used. The 260 potential participants were mailed an introductory letter (reminding them of their involvement in the prior study and inviting their participation in the current project), a newsletter (detailing findings from the original study), and a project information sheet.
Following consent, collection of blood samples was arranged using the phlebotomist at the Queensland University of Technology (QUT) or from a local commercial pathology collection center, as preferred by the participant. Approximately 8 mL of blood was drawn from the unaffected arm into yellow-top, ACD tubes, and was transferred to QUT's laboratory for processing. Upon receipt, samples were centrifuged, and the buffy coat (white cells) removed, aliquoted, labeled with a unique code, and stored at -80°C. Once samples were collected and processed from all participants, samples were transferred to the Queensland Institute of Medical Research, where genomic DNA was extracted from frozen buffy coat cells using the salting-out extraction method, quantified (Nanodrop Spectrophotometer ND-1000, Nanodrop Technologies, Wilmington, DE), diluted to a standardized concentration, and 12 ng of each sample plated onto 384-well plates for genotype analysis.
Genetic analyses
Tag single nucleotide polymorphisms (tagSNPs) that covered all known genetic variation in SOX18, VEGFC, VEGFD, VEGFR2, VEGFR3, RORC, FOXC2, LYVE1, ADM and PROX1 were selected for genotyping from HapMap data release 24/ phase II, November 2008, NCBI build 36, dbSNP b126 (www.hapmap.org), using the Tagger program within Haploview version 4.1 24 on CEU samples only. To minimize the number of genotypes tested while optimizing the number of polymorphisms evaluated, tagSNPs were chosen with an r 2 ‡ 0.8 using the pair-wise tagging approach. Several additional polymorphisms previously shown to have functional significance in primary lymphedema were also genotyped. To enhance coverage of each locus, we included SNPs within 5 kilobases (kb) of the 5' and 3' ends of each gene, based on the long splice variant where relevant.
SNPs were genotyped using iPLEX Gold assays on the Sequenom MassARRAY platform (Sequenom, San Diego, CA), as described previously. 25 There were four negative (H 2 O) controls per 384-well plate, and quality control parameters included genotype call rates > 95%, inclusion of 20 duplicate samples per 384-well plate ( > 5% of samples) with ‡ 98% concordance between duplicates, and Hardy-Weinberg Equilibrium p values ‡ 0.05. For assays not found to be polymorphic, rare-allele frequencies were confirmed using SPSmart (http://spsmart.cesga.es/). 26 Across the 10 genes investigated, 152 SNPs were attempted, but 16 SNPs failed assay design or quality control standards and hence were excluded from further analysis. After genotyping, the Broad Institute SNAP (SNP Annotation and Proxy Search) proxy search tool was used to determine SNPs tagged by genotyped tagSNPs for bioinformatics analyses, using the 1000 genomes SNP data set (http://www.broadinstitute.org/mpg/snap/ ldsearch.php). 27 GENETIC PREDISPOSITION TO SECONDARY LYMPHEDEMA 3
Statistical analyses
All statistical analyses were conducted by SPSS, version 18. The genotype frequency distributions among cases and controls were compared using unadjusted logistic regression analysis. Results are reported using odds ratios (ORs) with 95% confidence intervals (CI). Co-dominant mode of inheritance (i.e., rare-allele homozygote, heterozygote, and reference category of common-allele homozygote) was assumed in statistical analyses, using a trend test with 1 degree of freedom. Results were interpreted initially by means of p value ( < 0.05). However, because of the limited statistical power available, it was determined a priori that ORs > 2.0 (or equivalently, < 0.5) would be acknowledged, irrespective of statistical significance, as long as results conformed to a pattern consistent with straightforward Mendelian inheritance. This approach was considered appropriate for generation of hypotheses prior to seeking validation in larger studies, as is now common practice with breast cancer susceptibility genes. 28 
Results

Characteristics of the study participants
Of the 260 women invited to participate, a further 7 were found to be deceased, 22 did not respond to the invitation letter and could not be contacted, and 36 declined participation (primary reason: did not want to revisit illness). The remaining 195 women provided consent, 161 women provided a blood sample, and DNA was successfully extracted from 156 samples. Of these, 120 women had available data on the SOAC outcome measure used to define lymphedema status. Twenty-two women had evidence of lymphedema between 6-18 months post-diagnosis, while 98 had no evidence of lymphedema. Demographic and disease characteristics of participants in this case-control study were comparable to the initial research sample (Table 1) . Of note, the original cohort was shown to be representative of the wider Queensland breast cancer population. 9 Results of genetic analyses Table 2 provides an overview of the 10 genes under investigation. Not surprisingly, the more tagSNPs tested within a particular genetic locus and its flanking regions, the more likely we were to find a statistically significant trend test and/or genotype-specific ORs of a magnitude greater than 2.0 or less than 0.5. Only three loci revealed trend tests with p < 0.05, and these same genes contained larger numbers of genotype-specific ORs with extreme magnitudes that conformed with Mendelian expectations: VEGFR3, VEGFR2, and RORC (Table 2) . Table 3 presents detailed results for VEGFR3, VEGFR2, and RORC. Multiple elevated (or reduced) genotype-specific ORs occurred for adjacent tagSNPs in the 5' flanking region and exon/intron 1 of the three genes, where four of the five statistically significant results were found. VEGFR3 tagSNPs rs10464063, rs307814, and rs307811 (p trend = 0.039 and 0.040, respectively; in high linkage disequilibrium in our sample set), and rs11960332, as well as the polymorphisms covered by these SNPs, are all located in the 5' flanking region or intron 1 of the gene. Likewise, tagSNPs rs4284267, rs12128071, and rs11801866 (p trend = 0.037) are situated in these regions of the RORC gene, and VEGFR2 tagSNPs rs2239702 (p trend = 0.010) and rs7667298 tag many SNPs located in that gene's 5' flanking region, exon 1 and intron 1. Similar clustering was observed, but to a lesser extent, in the 3' flanking region of VEGFR3 (rs10055319 and rs11739214, p trend = 0.020) as well as tagSNPs rs6879285, rs1565818, and rs11747066 in intron 29 (long splice variant)/3' flanking region (short splice variant). Other regions of possible interest due to clustering of results occurred in VEGFR2 at intron 2 (rs1531290 and rs4576072) and intron 7 (rs10020464, rs17711073, rs2034965, and rs17085326) ( Table 3) .
Three additional genes showed minimal evidence of clustering based on the presence of two adjacent tagSNPs, sometimes close to an additional tagSNP, with genotypespecific ORs > 2.0 or < 0.5. These include rs11947611 and rs1485766, near rs6828869, all located deep in intron 4 of VEGFC; rs12089523 and rs10494972 in intron 4 of PROX1; and rs17318858 and rs17403620, near rs17403795, in the 3' region of LYVE1. The remaining tagSNPs with ORs beyond the a priori thresholds of interest are individually scattered across the length of the tested genes.
Conclusions
The Pulling Through Study was designed to investigate the development of lymphedema through prospective follow-up 
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of a cohort of Australian women recently treated for breast cancer. Among the women in our original cohort who presented with lymphedema according to objective assessment (n = 67), around 40% were not in any of the high-risk categories, which included receiving mastectomy, 20 + nodes excised, or treated on the nondominant side, 9, 29 suggesting that these factors were partial causes at best. This follow-up study now provides suggestive evidence for the involvement of the genes VEGFR2, VEGFR3, and RORC in the development of secondary lymphedema following breast cancer treatment. One or more tagSNPs in each of these genes showed a statistically significant association with lymphedema, and these individual results appeared within clusters of tagSNPs exhibiting odds ratios suggestive of altered lymphedema risk. All three genes code for receptor proteins, two of which come from the same gene family, and the clusters of noteworthy findings occur in analogous gene regions with potential biological function predicted on the basis of bioinformatic analysis.
Vascular endothelial growth factor (VEGF) is a key player in angiogenesis and lymphangiogenesis, and interacts with numerous proteins, including VEGFC and VEGFD and the receptors VEGFR2 and VEGFR3. 30 The VEGFC and VEGFD ligands stimulate lymphatic vessel growth 31, 32 and can ameliorate secondary lymphedema in mice. 33 VEGFC/D-induced lymphangiogenesis is mediated by VEGFR3, and VEGFR3 inhibition correlates with inhibition of lymphatic development and lymphedema; 34 their increased expression is associated with metastatic disease. 35 VEGFR3 has also been shown to cooperate with VEGFR2 in lymphatic vessel sprouting. 32 In addition, a hereditary form of lymphedema called Milroy disease (also known as familial primary congenital lymphedema (PCL)) has been attributed to nonfunctional forms of VEGFR3. 36, 37 It is therefore reasonable to hypothesize that more modest functional variations in these genes may predispose to secondary lymphedema.
Bioinformatic analysis of tagSNPs located in the 5' flanking region and exon/intron 1 of VEGFR2 and VEGFR3 that are associated with risk of lymphedema in our study revealed that these SNPs, or SNPs that are tagged by them, are predicted to have an effect on transcription factor binding sites. 38 An example is the common SNP rs10464063, located upstream of VEGFR3, which displayed substantially elevated ORs up to 8.29 (p trend = 0.053) for the rare-allele homozygote genotype. Of the nine SNPs tagged by this SNP (rs10464063 included), eight are predicted to alter transcription factor binding sites, 38 and hence may affect expression of VEGFR3. VEGFR2 tagSNP rs2239702 displayed the most significant p trend value (0.010) of all SNPs tested in this study, with an increased risk of secondary lymphedema up to 6.72 for the rare-allele homozygote genotype. Rs2239702 tags over 15 SNPs and four of these are predicted to alter transcription factor binding sites. 38 To our knowledge, the functional effects of these SNPs have not been investigated experimentally.
The other interesting region of the VEGFR3 gene involves three tagSNPs in intron 29 of the long splice variant or the 3' flanking region in the short version. TagSNPs rs6879285 and rs11747066 (which are highly correlated with each other, r 2 = 0.83) both tag rs1049095, located in the 3' untranslated region of the short splice variant of VEGFR3. This SNP is predicted to occur within two potential miRNA binding sites, 39 alteration of which could affect protein production. The third tagSNP, rs1565818, also tags the nonsynonymous SNP p.R1146H (rs1130379), a common polymorphism reported not to be associated with PCL. 18 However, the amino acid substitution is located in the cytoplasmic tyrosine kinase domain of VEGFR3, 40 where various mutations have been found in PCL families. 18, 36, 37 The functional effects of p.R1146H have not been reported, although bioinformatic analysis implies that this residue is not highly evolutionarily conserved and therefore is most likely a benign alteration; 41 nevertheless, the results from our study support further evaluation of this tagSNP and the polymorphisms it tags.
The only other statistically significant association we observed between a tagSNP and lymphedema occurred in the RORC gene. The functional significance of this member of the retinoid-related orphan receptor family remains unexplored in human secondary lymphedema; 42 however, in mice, this gene is essential for lymphoid organogenesis. 21 Also, one of its ligands, retinoic acid, recently has been shown to modulate lymphangiogenesis in vivo in the mouse embryo. 43 Similar to the two VEGF receptor genes, RORC tagSNP rs11801866 is located at the 5' end of RORC (in intron 1 of the commonly expressed splice variant 44 ). Both rs11801866 and another interesting tagSNP in this region, rs12128071, are predicted to affect transcription factor binding sites. 38 Two other genes had more limited evidence from this study for involvement in secondary lymphedema. PROX1 is a human homologue of the Drosophila homeobox gene prospero, expressed in lymphatic vessels of adults, and essential to maintain lymphatic endothelial cell identity. 45 However, the two tagSNPs with provocative findings located in intron 4 of PROX1 are now recognized to be in high linkage dysequilibrium with each other, and although they tag a large block of many SNPs, none are predicted to have any functional effect. 38 LYVE1 is a marker for commencement of lymphatic development, but the cluster of tagSNPS in the LYVE1 3' region (rs17318858 and rs17403620, near rs17403795) also had no predicted functional effects based on current knowledge. 38 To our knowledge, this is the first report evaluating potential genetic predisposition to secondary lymphedema following breast cancer diagnosis and treatment. It is based on rigorous follow-up of a population-based cohort of women with breast cancer to detect lymphedema based on objective measurements, followed by a systematic and thorough exploration of polymorphisms in 10 genes of potential interest to the etiology of secondary lymphedema. Bonferroni correction was not applied, as this is considered overly conservative for a hypothesis-generating study. The most significant limitation of the study relates to its small sample size. Although 67 cases had been identified via clinical assessment in the Pulling Through Study at the time of funding, attrition was much higher than anticipated between the 18-month examination and the 6-year follow-up, in part due to more difficulty obtaining blood samples from all previous participants and a higher mortality rate than expected among the women with lymphedema. 46 Also, it is plausible that some of the woman classified as controls had developed lymphedema between the 18-month post-diagnosis assessment and 6-year blood draw, making it more difficult to find clinically and statistically significant differences between our cases and controls. Nevertheless, despite the limited statistical power, we identified two genetic loci from the same biological family, VEGFR2 and VEGFR3, and a third gene, RORC, to have clusters of interesting results for SNPs located in analogous parts of the genes. Moreover, a number of these SNPs could potentially influence transcription factor binding sites and protein production. Many of these polymorphisms are sufficiently common to be of potential public health importance if these associations are genuine, for example, minor allele frequencies between 20%-40% for SNPs in the two VEGFR genes.
In summary, this research extends findings from primary congenital lymphedema and animal models to secondary lymphedema following cancer diagnosis. The possibility that the three receptor genes identified confer genetic predisposition to secondary lymphedema following breast cancer treatment warrants further attention for potential replication using larger datasets. If confirmed, understanding the role of inherited genetic variation in lymphedema pathogenesis could lead to improvements in clinical management of breast cancer patients. First, with constant improvements in genome-wide sequencing technology and lowering of genotyping costs for clinical use, it is possible to envision identification of lymphedema molecular signature/s that could aid in the prediction and modified management of women at risk. This information could be used to target women for monitoring of lymphedema status and rapid referral to specialized care. It has been suggested that early detection of lymphedema may facilitate more effective management, resulting in reduced severity and associated disability. 47 The emergence of new technologies in drug design and development, combined with the identification of novel molecular targets specific to the onset of lymphedema, also may enable further development of tailored therapies, both for treatment and prevention of the condition. Finally, although the findings in this study are specifically relevant to breast cancer, if confirmed, there are implications for other patients at risk of secondary lymphedema following injury, melanoma, or gynecological, prostate, or head and neck cancers.
